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The average cost per prescription was R634.76 for donepezil, and R551.35 for 
memantine. Only 5.27% of patients were prescribed more than one active ingredient 
for Alzheimer’s disease during the year (mostly donepezil or galantamine, together 
with memantine). Average Prescribed Daily Doses (PDDs) of all active ingredients 
were generally lower than their respective Deﬁned Daily Doses (DDDs). The average 
PDD for donepezil was 7.45 mg (DDD  7.5 mg), galantamine 13.56 mg (DDD  
16 mg), for memantine was 17.46 mg (DDD  20 mg) and for rivastigmine was 
6.89 mg (DDD  9 mg). CONCLUSIONS: The results were similar to those of previ-
ous South African studies. Treatment outcomes could not be measured and it is recom-
mended that qualitative studies be undertaken to determine the cost-effectiveness of 
the different treatment options according to family members and caretakers.
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OBJECTIVES: Prescribing an initial optimum therapeutic dose while avoiding dose-
related side effects is important in the treatment of major depressive disorder (MDD). 
Many factors may inﬂuence a physician’s decision on an antidepressant choice and 
starting dose. The purpose of the present study was to identify the pretreatment predic-
tors of initial high-dose prescription of duloxetine in patients with MDD in real world 
clinical settings. METHODS: A total of 10,128 patients with MDD who were selected 
from a large commercially administrative claims database and were initiated on 
duloxetine between July 1, 2005 and June 30, 2006 were included in the analysis. 
Patients had no prescriptions of duloxetine in the 6 months prior to duloxetine treat-
ment. For patients who had continuous enrollment for 12 months prior to duloxetine 
treatment, the associations between demographic characteristics and pre-initiation 
clinical variables in the prior 1 year and initial high-dose (60 mg/day) prescription 
compared with average dosage (60 mg/day) prescription were examined by logistic 
regression. RESULTS: Of the sample, 31.2% were initially prescribed duloxetine less 
than 60 mg/day; 62.1%, 60 mg/day; and 6.8%, 60 mg/day. Compared with average-
dose patients, high-dose patients had more comorbidities; used more benzodiazepine, 
anxiolytics, atypical antipsychotics, lithium, psychostimulants, and anticonvulsants; 
and used more medical care services with higher pharmacy and medical costs in the 
prior 1 year. After adjustment for health plan type and geographic region of residence, 
the following factors were independently associated with initial high-dose prescription: 
prior use of psychostimulants (OR  1.45), no prior use of selective serotonin reuptake 
inhibitors (OR  1.28), physician specialty (psychiatrist vs. non-psychiatrist, OR  
1.43), and high medical cost in the prior 1 year (OR  2.12). CONCLUSIONS: 
 Multiple demographic and clinical characteristics and prior health care service utiliza-
tion are associated with initial high-dose duloxetine prescription. High-dose patients 
may represent a group of complex patients with high medical cost who need intensive 
medical intervention.
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OBJECTIVES: The appropriate and optimal health care resources of schizophrenic 
patients could beneﬁt from identifying predictive factors for hospitalization. The 
purpose of this study was to identify those factors of hospitalization for French 
schizophrenic patients out of a 2 years prospective cohort of 288 patients. METHODS: 
This study collected clinical, patient reported outcomes, patient management, care 
giver involvement and resource utilizations data every six months. The patients who 
were at least once hospitalized during the study were compared to the patients who 
were not hospitalized during the study. Predictive factors of hospitalization were 
identiﬁed by using a Cox model with all appropriate variables. RESULTS: To be under 
antidepressant/depressed, to have negative attitude toward medicine and former hos-     
pitalizations appear to be good predictors of hospitalisation in French schizophrenic 
patients. While living alone and subjective side effect were associated to reduce the 
risk of hospitalisation. Depression is known to be associated to poor outcome however 
few comprehensive studies include depression as a confounding factor. Negative atti-
tude toward medicine as well as former hospitalisation are likely to be associated to 
increase the risk of hospitalisation. Unexpectedly perceived side effects and living alone        
were associated to reduce hospitalisation. The authors do not have clear explanation 
but hypothesis that would require to be tested in further studies. CONCLUSIONS: 
Unless appropriate confounding variables are included in resource utilization studies, 
results should considered with great caution.
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OBJECTIVES: to assess the prevalence, incidence and persistence of AntiDepressant         
(AD) drug therapy in an area of Campania, a region in the South of Italy, during the 
years 2005–2007. METHODS: we collected, from an administrative prescription      
database covering a population of 441,317 individuals, all prescriptions for ADs 
reimbursed in the years 2005–2007. We calculated the number of subjects receiving 
at least one ADs prescription, to estimate the annual prevalence and incidence of AD 
users. Among incidence users we evaluated the percentage of individuals remaining 
on therapy at 12 months following the ﬁrst observed AD prescription. The cumulative 
persistence of each medication was estimated using the Kaplan-Meier method. We      
identiﬁed users of different ADs types: tricyclic antidepressants (TCAs), selective 
serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibi-    
tors (SNRIs) and other antidepressants.   RESULTS: A progressive rise in prevalence     
rates was observed during the 3-years period. 1-year prevalence of AD use was 5.08 
per 100,000 inhabitants in the year 2007. Prevalence was higher for females (2005: 
5.67; 2006: 6.15; 2007: 6.61) and increased during three years period with increasing 
age. Prevalence of SSRI usage markedly increased from 3.45 in 2005 to 4.04 in 2007. 
A 1-year incidence of AD treatment was 2.79 per 100,000 person-year in 2006. SSRIs 
accounted for almost two-thirds of total new treatments with ADs. The analysis of 
therapy persistence revealed that the 80% of AD users discontinued medication within 
60 days; there are no difference among different drug classes. CONCLUSIONS: The 
results of the study indicated an increasing prevalence of AD medication usage during 
the 2005–2007 years. This increase appears to be mostly related to SSRI, in particular 
those recently marketed. The non-persistence is very frequent in AD users, only rarely 
the duration of treatment was consistent with recommendations for depression 
therapy.
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As a ﬁrst step to model schizophrenia, we are proposing a research project aimed at 
better understanding the factors associated with speciﬁc disease states associated 
with schizophrenia. OBJECTIVES: To evaluate the factors associated with the risk of 
being in a speciﬁc disease state of schizophrenia. METHODS: The model was based 
on data from RAMQ and Med-Echo databases. A total of 12,754 newly diagnosed 
patients with schizophrenia patients were identiﬁed. Six discrete disease states were 
deﬁned within the model (ﬁrst episode—FE, low dependency state—LDS, high depen-
dency state—HDS, Stable, Well and Death) and patients’ movements between these 
disease states enabled 17 risks to be identiﬁed. To evaluate factors associated to the 
risk of being in each disease state, we constructed ﬁve risk functions based on Cox 
proportional hazard analysis for competing risks. The risk factors included in the 
models were age, gender, social assistance status, severity of schizophrenia, depression, 
anxiolytic drugs use and other mental disorders. RESULTS: After the FE of schizo-
phrenia, 69.8% of patients transitioned to LDS, 11.2% to HDS, 1% to the death 
state and 18% into the Well state. Being male (HR: 0.93, 95% CI: 0.89–0.97) or 
older (HR: 0.94, 95% CI: 0.91–0.96) was associated with a decreasing risk of moving 
to LDS after being FE. In contrast, being on social assistance, depressed, using anxio-
lytic drugs or being diagnosed with other mental disorders were associated with 
an increased risk of being in a LDS after a FE, ranging from 1.11 to 1.55 folds. 
CONCLUSIONS: Some of our results are consistent with those obtained from the 
published literature. Based on these risk functions we estimate individual transition 
probabilities that will be used in the ﬁrst Canadian model of schizophrenia incorporat-
ing transition probabilities adjusted for individual risk factors proﬁles using Canadian 
data.
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OBJECTIVES: In Western Hungary the number of women with hypertension increased 
with 21%, the number of patients with ischemic heart problems increased with 46% 
between 2005 and 2007. The most probable reason of this sudden increase among 
the life quality factors is the increasing of chronic stress. The rate of chronic stress 
and the effectiveness of coping were measured between workers from a regional mul-
tinational ﬁrm with a cross sectional examination in 2008. METHODS: Sampling is 
representative regarding to the Western Hungarian population, 900 workers were 
examined with unknown presumption. Data collection was made with Richard Rahe 
Short Questionnaire about Stress and Coping standard measurement device. The 
analysis of the data was done with SPSS 17.0 and Epi Info 3.5.1 programs, two sample 
t-test and logistic regression calculation was made. RESULTS: From the ﬁve scales 
measuring stress women showed alarming signs on three scales (sanitary problems, 
psychological symptoms and the A- and C-type personal characteristic scales), and 
men on one scale (the A- and C-type personal characteristic). The difference is signiﬁ-
cant (p  0.000). From the ﬁve scales measuring coping men and women equally 
showed alarming signs on the social support scale as a deﬁcit. Women ﬁght against 
stress with less efﬁciency on the scale of habits related to health (p  0.001). The most 
deﬁning stress indicating factor in case of man is sanitary problems (OR  2.27, p  
0.02), and personal characteristics in case of woman (OR  3.34, p  0.002). The 
most important inﬂuencing factor in case of coping is the sense of coherence (at women 
OR  7.9, p  0.000, at men OR  4.5, p  0.000). CONCLUSIONS: This survey 
shows that chronic stress is complex, but it can be examined individually and in teams 
with proper methods. This topic is current in relation to national health: chronic 
